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ing in RCC.6,7 AFP is not specific and 
can be negative in HCC.6
In conclusion, tumorttottumor 
metastasis is an infrequent, but not 
a rare event. HCCttotRCC metast
tasis is rare and can be considered 
as one of the rarest cancerttotcant
cer metastasis. Sometimes, it can be 
morphologically difficult to distint
guish between HCC and RCC. This 
could present diagnostic challenges 
to the pathologist, particularly on 
the frozen section. Simple immunot
histochemistry panel of HepPart1 
and CD10 is helpful to distinguish 
between the two neoplasms.
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CD123 monoclonal anti-
body in myelodysplastic 
syndrome
To the Editor: CD123 monoclot
nal antibody is an IL3Ra antirecept
tor useful in the diagnosis of hairy 
cell leukemia.1 It is widely used to 
recognize minimal residual disease 
(MRD) in treated acute myeloid 
leukemia (AML). We studied 20 pat
tients with a diagnosis of myelodyst
plastic syndrome (MDS). The most 
prominent clinical sign was leukot
penia with variable lymphocytosis, 
and disease evolution of more than a 
year. Patient ages ranged between 32 
to 81 years, and included 11 women 
and 9 men. Laboratory bone mart
row findings were consistent with 
hypercellular and heteromorphous 
cytology with erythroid dysplasia 
and the presence of PelgertHuett 
anomaly, with increased intermedit
ate forms, immature myeloid series 
and macroplatelets. Serum iron 
and ferritin were measured and 
one marrow iron and biopsy were 
obtained. Flow cytometry monot
clonal antibodies used included 
CD34 + CD123, CD38 + CD123, 
CD34 + CD117, CD34 + CD38, 
CD123, and p53 and Bcl2. These 
monoclonal combinations were 
studied to determine the presence 
of leukemic stem cells (LSC). The 
analysis showed evidence of CD123 
in 12 patients, with more than 20% 
(range, 22%t66%). In the remaint
ing 8 patients, CD123 was less than 
20% (range, 6%t16%). The CD34 
+ CD117 combination findings 
corresponded with 16%t56%s. The 
patient samples were also marked 
with CD38, with a presence of 
39%t82%, indicating cellular activat
tion. When compared with CD34 
+ CD123, the range was 20%t95%. 
Taking into account total positivity, 
all our patients had an increased 
presence of CD123, in addition to 
CD34 and CD117. Eleven (n=11) 
patients presented with alterat
tions in p53, and 14 had the prest
ence BCL2 oncogene. Patients with 
more than 20% CD123 were treated 
with antitmethylation drugs. Our 
conclusions indicate that the use 
of CD123 with other immaturity 
markers corresponds with MDS 
and relates to the presence of LSC. 
The use of this marker may help in 
early identification and treatment of 
cases with higher potential for leut
kemic transformation.  Limited but 
similar findings have been reported 
about the value of CD123, under 
comparable conditions.2 
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